Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion.
OBJECTIVE
To report the long-term impact of two cycles of adjuvant chemotherapy on relapse rates and treatment-related morbidity in high-risk stage I nonseminomatous testicular germ cell tumors (NSGCTT I).


METHODS
From April 1987 to September 1997, 40 stage I NSGCTT patients with evidence of vascular invasion and/or embryonal carcinoma (EC) in the orchidectomy specimen were treated with two courses of bleomycin, cisplatin, and etoposide (BEP).


RESULTS
All patients but one (incidental death) were alive after an extended follow-up (median 113.2 months, range 63-189). No patients relapsed but two patients presented a second cancer in the remaining testis. Short-term toxicity was minimal and no long-term toxicity was observed.


CONCLUSIONS
The present series, with extensive follow-up, demonstrated that the efficacy and toxicity of two cycles of BEP compared well with the results of surveillance strategies or RPLND in high-risk stage I NSGCTT.
Chevreau
Christine
C
Department of Medical Oncology, Institut Claudius Regaud, 20, 24 rue du Pont Saint Pierre, 31052 Toulouse Cedex, France.
Mazerolles
Catherine
C
Soulié
Michel
M
Gaspard
Marie-Hélène
MH
Mourey
Loïc
L
Bujan
Louis
L
Plante
Pierre
P
Rischmann
Pascal
P
Bachaud
Jean-Marc
JM
Malavaud
Bernard
B
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001761:Bleomycin / Q000008:administration & dosage*; D018236:Carcinoma, Embryonal / Q000188:drug therapy* / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage*; D005047:Etoposide / Q000008:administration & dosage*; D005500:Follow-Up Studies; D018237:Germinoma / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D009378:Neoplasms, Multiple Primary / Q000188:drug therapy* / Q000473:pathology; D012307:Risk Factors; D015996:Survival Rate; D013736:Testicular Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013997:Time Factors; D019043:Vascular Neoplasms / Q000188:drug therapy* / Q000473:pathology
D001761:Bleomycin; D005047:Etoposide; D002945:Cisplatin